{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04373785",
            "orgStudyIdInfo": {
                "id": "NG101m"
            },
            "organization": {
                "fullName": "NeuGATE Theranostics",
                "class": "INDUSTRY"
            },
            "briefTitle": "NG101m Adjuvant Therapy in Glioblastoma Patients",
            "officialTitle": "A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients",
            "therapeuticArea": [
                "Other"
            ],
            "study": "adjuvant-therapy-in-glioblastoma-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-04",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-07-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-04-30",
            "studyFirstSubmitQcDate": "2020-04-30",
            "studyFirstPostDateStruct": {
                "date": "2020-05-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-04-13",
            "lastUpdatePostDateStruct": {
                "date": "2023-04-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NeuGATE Theranostics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m capsules along with the standard treatment of temozolomide and radiation.",
            "detailedDescription": "Glioblastoma multiforme (GBM) is the most lethal form of malignant brain cancer, with about 12,000 new cases diagnosed each in the the United States. The current standard treatment consists of maximal, safe resection, followed by radiation therapy of 60 Gray (Gy) with concomitant oral temozolomide (TMZ) for 6 weeks, then continue with six cycles of high-dose temozolomide. The median survival rate for newly diagnosed GBM patients is 14.6 months with a 2-year overall survival (OS) rate of 27.2%. This clinical trial evaluates the 2-year OS of oral NG101m as an adjuvant therapy to chemoradiotherapy in newly diagnosed GBM subjects."
        },
        "conditionsModule": {
            "conditions": [
                "Glioblastoma Multiforme"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Radiation: Radiotherapy Drug: Temozolomide Drug: NG101m",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 52,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "NG101m and standard treatment",
                    "type": "EXPERIMENTAL",
                    "description": "Concomittant therapy:\n\nRadiation therapy, oral temozolomide, and oral NG101m\n\nAdjuvant therapy:\n\nOral temozolomide and oral NG101m",
                    "interventionNames": [
                        "Radiation: Intensity-modulated radiation therapy",
                        "Drug: Temozolomide",
                        "Drug: NG101m"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "RADIATION",
                    "name": "Intensity-modulated radiation therapy",
                    "description": "Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.",
                    "armGroupLabels": [
                        "NG101m and standard treatment"
                    ],
                    "otherNames": [
                        "radiation therapy"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Temozolomide",
                    "description": "Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.\n\n1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles.",
                    "armGroupLabels": [
                        "NG101m and standard treatment"
                    ],
                    "otherNames": [
                        "Temodar"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "NG101m",
                    "description": "Oral NG101m capsule continuously twice daily.",
                    "armGroupLabels": [
                        "NG101m and standard treatment"
                    ],
                    "otherNames": [
                        "NG101m regimen"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with treatment-emergent adverse events and serious adverse events",
                    "description": "Safety and tolerability of NG101m as adjuvant therapy to chemoradiation therapy",
                    "timeFrame": "1 month"
                },
                {
                    "measure": "Efficacy of NG101m adjuvant chemoradiation therapy assessed by measuring 2-year overall survival rate.",
                    "description": "Efficacy of NG101m adjuvant therapy will be assessed by measuring 2-year overall survival rate.",
                    "timeFrame": "24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "Assess the duration of PFS",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Response assessment in neuro-oncology (RANO) criteria",
                    "description": "Radiological response to adjuvant NG101m therapy",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Quality of Life (QoL)",
                    "description": "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)",
                    "timeFrame": "24 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Identify and quantify immune/effector cells",
                    "description": "Cytokines measurement",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female subjects \u2265 18 years of age\n* Must be newly diagnosed with GBM\n* Primary treatment must consist of a chemoradiation therapy (CRT) regimen\n* Hemoglobin \\> 9 g/dL\n* White blood count 3,600 - 11,000/mm3\n* Absolute neutrophil count (ANC) \u2265 1,500/mm3\n* Absolute lymphocyte count (ALC) \u2265 1,000/mm3\n* Platelet count 100,000/mm3\n* BUN \u2264 1.5 times upper limit of normal\n* Creatinine clearance rate \\> 40 mL/min\n* ALT \u2264 3 times upper limit of normal\n* AST \u2264 3 times upper limit of normal\n* Alkaline phosphatase \u2264 3 times upper limit of normal\n* Total bilirubin \u2264 2.0 mg/dL\n* Karnofsky Performance Status \u2265 70\n* Must not be on any other alternative therapies\n* Not pregnant\n\nExclusion Criteria:\n\n* Known hypersensitivity to meloxicam, famotidine, and/or caffeine or any of their derivatives or components\n* Known allergy to vitamin A, vitamin D3, and/or L-citrulline\n* Pregnant women\n* Breastfeeding women\n* Corticosteroid therapy that cannot be tapered down to a dose of 1 - 2 mg/day of dexamethasone or its equivalent\n* History of immunodeficiency diseases or autoimmune diseases\n* History of peptic ulcer disease or gastrointestinal perforation",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Thien Tran, PharmD",
                    "role": "CONTACT",
                    "phone": "713-534-1300",
                    "email": "TTran@NeuGATE.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Yvonne Kew, MD, PhD",
                    "affiliation": "NeuGATE Theranostics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Yvonne Kew MD, PLLC",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Thien Tran, Pharm.D.",
                            "role": "CONTACT",
                            "phone": "713-534-1300",
                            "email": "Thien@DrKew.com"
                        },
                        {
                            "name": "Yvonne Kew, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005909",
                    "term": "Glioblastoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001254",
                    "term": "Astrocytoma"
                },
                {
                    "id": "D000005910",
                    "term": "Glioma"
                },
                {
                    "id": "D000018302",
                    "term": "Neoplasms, Neuroepithelial"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9019",
                    "name": "Glioblastoma",
                    "asFound": "Glioblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4561",
                    "name": "Astrocytoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M9020",
                    "name": "Glioma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20446",
                    "name": "Neoplasms, Neuroepithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T2518",
                    "name": "Glioblastoma",
                    "asFound": "Glioblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2519",
                    "name": "Glioma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077204",
                    "term": "Temozolomide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1692",
                    "name": "Temozolomide",
                    "asFound": "Cervical",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}